Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Oligodendroglioma 2Astrocytoma 2Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1362Gemcitabine 1235Bevacizumab 1226Paclitaxel 1214Radiotherapy 1176Docetaxel 1080pembrolizumab 1029Oxaliplatin 936Capecitabine 902Fluorouracil 833Rituximab 729Doxorubicin 684Nivolumab 679Dexamethasone 667Etoposide 660Irinotecan 622Leucovorin 576Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 470Cytarabine 467Magnetic Resonance Spectroscopy 461Filgrastim 446Prednisone 433Specimen Handling 411Lenalidomide 410Vincristine 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × talampanel × Clear all
NCT00267592 2016-05-19

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
72 enrolled
CNS

Glioblastoma

NCT00064363 2012-03-08

Talampanel in Treating Patients With Recurrent High-Grade Glioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
30 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡